Molecular Mechanisms for Lipopolysaccharide-induced Biphasic Activation of Nuclear Factor-κB (NF-κB)*
暂无分享,去创建一个
I. Choi | S. Im | H. Ko | Hyun-Suk Lee | H. Lee | Jung-hwa Choi | Su-Ji Han | K. Seo | E. Choi | Jung-Hwa Choi | Hyun-Suk Lee
[1] T. Mak,et al. Severe impairment of interleukin-1 and Toll-like receptor signalling in mice lacking IRAK-4 , 2002, Nature.
[2] T. Lawrence,et al. Possible new role for NF-κB in the resolution of inflammation , 2001, Nature Medicine.
[3] S. Im,et al. Platelet-Activating Factor-Induced Early Activation of NF-κB Plays a Crucial Role for Organ Clearance of Candida albicans1 , 2001, The Journal of Immunology.
[4] B. Beutler,et al. The evolution and genetics of innate immunity , 2001, Nature Reviews Genetics.
[5] D. Goeddel,et al. Defective Lymphotoxin-β Receptor-Induced NF-κB Transcriptional Activity in NIK-Deficient Mice , 2001, Science.
[6] B. Aggarwal,et al. Tumour necrosis factors receptor associated signalling molecules and their role in activation of apoptosis, JNK and NF-κB , 2000, Annals of the rheumatic diseases.
[7] K. Jang,et al. Selective Involvement of Reactive Oxygen Intermediates in Platelet-activating Factor-mediated Activation of NF-κB , 2000, Inflammation.
[8] L. O’Neill. The Toll/interleukin-1 receptor domain: a molecular switch for inflammation and host defence. , 2000, Biochemical Society transactions.
[9] J. Simpson,et al. A Double-Blind Placebo-Controlled Study of an Infusion of Lexipafant (Platelet-Activating Factor Receptor Antagonist) in Patients with Severe Sepsis , 2000, Antimicrobial Agents and Chemotherapy.
[10] J. Vincent,et al. Phase II multicenter clinical study of the platelet‐activating factor receptor antagonist BB‐882 in the treatment of sepsis , 2000, Critical care medicine.
[11] S. Akira,et al. Unresponsiveness of MyD88-deficient mice to endotoxin. , 1999, Immunity.
[12] T. Serikawa,et al. Alymphoplasia is caused by a point mutation in the mouse gene encoding Nf-κb-inducing kinase , 1999, Nature Genetics.
[13] S. Morony,et al. TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. , 1999, Genes & development.
[14] I. Choi,et al. Glucocorticoids prevent NF‐κB activation by inhibiting the early release of platelet‐activating factor in response to lipopolysaccharide , 1999, European journal of immunology.
[15] M. Peppelenbosch,et al. PHOSPHOLIPASE A2INHIBITORS AND LEUKOTRIENE SYNTHESIS INHIBITORS BLOCK TNF-INDUCED NF-κB ACTIVATION , 1999 .
[16] B. Johansen,et al. Selective inhibitors of cytosolic or secretory phospholipase A2 block TNF-induced activation of transcription factor nuclear factor-kappa B and expression of ICAM-1. , 1998, Journal of immunology.
[17] Z. Cao,et al. MyD88: an adapter that recruits IRAK to the IL-1 receptor complex. , 1997, Immunity.
[18] P. Feng,et al. IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. , 1997, Science.
[19] S. Im,et al. Involvement of nuclear factor‐xB in platelet‐activating factor‐mediated tumor necrosis factor‐α expression , 1997 .
[20] W. Goebel,et al. Listeria monocytogenes infection of P388D1 macrophages results in a biphasic NF-κB (RelA/p50) activation induced by lipoteichoic acid and bacterial phospholipases and mediated by IκBα and IκBβ degradation , 1997 .
[21] N. B. Lerner,et al. Rickettsia rickettsii infection of cultured human endothelial cells induces NF-kappaB activation , 1997, Infection and immunity.
[22] P. Insel,et al. Dual role of protein kinase C in the regulation of cPLA2-mediated arachidonic acid release by P2U receptors in MDCK-D1 cells: involvement of MAP kinase-dependent and -independent pathways. , 1997, The Journal of clinical investigation.
[23] D. Wallach,et al. MAP3K-related kinase involved in NF-KB induction by TNF, CD95 and IL-1 , 1997, Nature.
[24] Michael Karin,et al. Dissection of TNF Receptor 1 Effector Functions: JNK Activation Is Not Linked to Apoptosis While NF-κB Activation Prevents Cell Death , 1996, Cell.
[25] Zhaodan Cao,et al. TRAF6 is a signal transducer for interleukin-1 , 1996, Nature.
[26] S. Im,et al. Augmentation of tumor metastasis by platelet-activating factor. , 1996, Cancer research.
[27] Z. Cao,et al. IRAK: A Kinase Associated with the Interleukin-1 Receptor , 1996, Science.
[28] S. Huong,et al. Human cytomegalovirus upregulates NF-kappa B activity by transactivating the NF-kappa B p105/p50 and p65 promoters , 1995, Journal of virology.
[29] Jiahuai Han,et al. Platelet-activating Factor Induces NF-κB Activation through a G Protein-coupled Pathway (*) , 1995, The Journal of Biological Chemistry.
[30] F. Santini,et al. Activation of the mitogen-activated protein kinase/cytosolic phospholipase A2 pathway in a rat mast cell line. Indications of different pathways for release of arachidonic acid and secretory granules. , 1995, Journal of immunology.
[31] S. Nourshargh,et al. Interleukin-1-induced leukocyte extravasation across rat mesenteric microvessels is mediated by platelet-activating factor. , 1995, Blood.
[32] H. Erdjument-Bromage,et al. IκB-β regulates the persistent response in a biphasic activation of NF-κB , 1995, Cell.
[33] G. Camussi,et al. Tumor necrosis factor alpha-induced angiogenesis depends on in situ platelet-activating factor biosynthesis , 1994, The Journal of experimental medicine.
[34] W. Shearer,et al. Activation of NF-KB and Immunoglobulin Expression in Response to Platelet-Activating Factor in a Human B Cell Line , 1994 .
[35] J. Sedor,et al. Cell-specific regulation of type II phospholipase A2 expression in rat mesangial cells. , 1993, The Journal of clinical investigation.
[36] R. Heller,et al. Cytoplasmic phospholipase A2 activity and gene expression are stimulated by tumor necrosis factor: dexamethasone blocks the induced synthesis. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[37] M. Krönke,et al. TNF activates NF-κB by phosphatidylcholine-specific phospholipase C-induced “Acidic” sphingomyelin breakdown , 1992, Cell.
[38] D. Gingras,et al. Platelet-activating factor (PAF-acether) enhances the concomitant production of tumour necrosis factor-alpha and interleukin-1 by subsets of human monocytes. , 1991, Immunology.
[39] G. Camussi,et al. Synthesis and release of platelet-activating factor by human vascular endothelial cells treated with tumor necrosis factor or interleukin 1 alpha. , 1988, The Journal of biological chemistry.
[40] D. Baltimore,et al. Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-κB transcription factor , 1988, Cell.
[41] L. Touqui,et al. Perspectives in platelet-activating factor research. , 1987, Pharmacological reviews.
[42] David Baltimore,et al. Multiple nuclear factors interact with the immunoglobulin enhancer sequences , 1986, Cell.
[43] J. Mato,et al. Modulation of lyso-platelet-activating factor: acetyl-CoA acetyltransferase from rat splenic microsomes. The role of calcium ions. , 1985, Biochimica et biophysica acta.
[44] L. Touqui,et al. 1-O-alkyl-2-acyl-sn-glycero-3-phosphorylcholine is the precursor of platelet-activating factor in stimulated rabbit platelets. Evidence for an alkylacetyl-glycerophosphorylcholine cycle. , 1985, Biochimica et biophysica acta.
[45] M J May,et al. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. , 1998, Annual review of immunology.
[46] G. Atsumi,et al. Regulatory functions of phospholipase A2. , 1997, Critical reviews in immunology.
[47] E. Kopp,et al. NF-kappa B and rel proteins in innate immunity. , 1995, Advances in immunology.
[48] W. J. Johnson,et al. Interleukin-1 and tumor necrosis factor are not synergistic for human synovial fibroblast PLA2 activation and PGE2 production. , 1988, Prostaglandins.